Filing Flows › CorMedix (CRMD) › Guidance & outlook
CorMedix (CRMD) guidance and outlook
CorMedix (CRMD) reaffirmed its guidance on Nov 2, 2026: Revenue (segment) $325M–$345M for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $325M–$345M | reaffirmed |
From the earnings release filed Nov 2, 2026 (8-K on EDGAR).
CorMedix's latest quarter
CorMedix, Q2 2026: revenue $102M (+156% year over year), operating margin 42.1%, net earnings $26.0M, operating cash flow $86.2M. The chart follows the revenue to costs, profit and cash.
Questions
Did CorMedix raise or lower its guidance?
CorMedix (CRMD) reaffirmed its guidance on Nov 2, 2026: Revenue (segment) $325M–$345M for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.